產品屬性：
產品名稱 | MN58b |
規(guī)格 | 1mg |
貨號 | EY-01Y12309 |
Cas No.: 203192-01-2
別名: N/A
化學名: N/A
分子式: C32H40Br2N4
分子量: 640.49
溶解度: DMSO: 14.71 mg/mL (22.97 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
MN58b is a selective choline kinase α (CHKα) inhibitor, and results in inhibition of phosphocholine synthesis. MN58b reduces cell growth through the induction of apoptosis, and also has antitumoral activity[1][2].The IC50s of MN58b for parental and Gemcitabine-resistant Suit2 007 cells are 3.14 μM and 0.77 μM, respectively[1].MN58b (1-5 μM; 72 hours; SK-PC-1, Suit2 008, IMIM-PC2, and RWP-1 cells) has a marked effect on colony formation at 1 μM, and growth is completely abolished at 5 μM in all the cell lines[1].MN58b ((1-10 μM; 24-48 hours; SK-PC-1, Suit2 008, IMIM-PC2, and RWP-1 cells) induces apoptosis and this response correlates with CHKα expression[1].Cell Viability Assay[1] Cell Line:SK-PC-1, Suit2 008, IMIM-PC2, and RWP-1 cellsMN58b (4 mg/kg; intraperitoneal injection; once a day; for 5 days; MF-1 nude mice) treatment significantly decreases phosphomonoesters in both HT29 and MDA-MB-231 xenografts. Phosphocholine levels are found to correlate with choline kinase activities[2].Animal Model:MF-1 nude mice with HT29 or MDA-MB-231 cells[2][1]. Mazarico JM, et al. Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Mol Cancer Ther. 2016 Feb;15(2):323-33.
[2]. Al-Saffar NM, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006 Jan 1;66(1):427-34.
特別提醒公司產品僅供科研使用
